Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysis
<h4>Background</h4> SHP2 is a latent biomarker for predicting the survivals of solid tumors. However, the current researches were controversial. Therefore, a meta-analysis is necessary to assess the prognosis of SHP2 on tumor patients. <h4>Materials and methods</h4> Searched...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782321/?tool=EBI |
| _version_ | 1818954263666098176 |
|---|---|
| author | Jiupeng Zhou Hui Guo Yongfeng Zhang Heng Liu Quanli Dou |
| author_facet | Jiupeng Zhou Hui Guo Yongfeng Zhang Heng Liu Quanli Dou |
| author_sort | Jiupeng Zhou |
| collection | DOAJ |
| description | <h4>Background</h4> SHP2 is a latent biomarker for predicting the survivals of solid tumors. However, the current researches were controversial. Therefore, a meta-analysis is necessary to assess the prognosis of SHP2 on tumor patients. <h4>Materials and methods</h4> Searched in PubMed, EMBASE and web of science databases for published studies until Jun 20, 2021. A meta-analysis was performed to evaluate the affect of SHP2 in clinical stages, disease-free survival (DFS) and overall survival (OS) in tumor patients. <h4>Results</h4> This study showed that the expression of SHP2 had no significant correlation with clinical stages (OR: 0.91; 95% CI, 0.60–1.38; P = 0.65), DFS (HR = 0.88; 95%CI: 0.58–1.34; P = 0.56) and OS (HR = 1.07, 95%CI: 0.79–1.45, P = 0.67), but the prognostic effect varied greatly with tumor sites. High SHP2 expression was positively related to early clinical stage in hepatocellular carcinoma, not associated with clinical stage in the most of solid tumors, containing laryngeal carcinoma, pancreatic carcinoma and gastric carcinoma, etc. Higher expression of SHP2 could predict longer DFS in colorectal carcinoma, while predict shorter DFS in hepatocellular carcinoma. No significant difference was observed in DFS for non-small cell lung carcinoma and thyroid carcinoma. Higher SHP2 expression was distinctly related to shorter OS in pancreatic carcinoma and laryngeal carcinoma. The OS of the other solid tumors was not significantly different. <h4>Conclusions</h4> The prognostic value of SHP2 might not equivalent in different tumors. The prognostic effect of SHP2 is highly influenced by tumor sites. |
| first_indexed | 2024-12-20T10:19:23Z |
| format | Article |
| id | doaj.art-0bcbb0735d6d4a59839ee756dffac90e |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T10:19:23Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-0bcbb0735d6d4a59839ee756dffac90e2022-12-21T19:43:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01171Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysisJiupeng ZhouHui GuoYongfeng ZhangHeng LiuQuanli Dou<h4>Background</h4> SHP2 is a latent biomarker for predicting the survivals of solid tumors. However, the current researches were controversial. Therefore, a meta-analysis is necessary to assess the prognosis of SHP2 on tumor patients. <h4>Materials and methods</h4> Searched in PubMed, EMBASE and web of science databases for published studies until Jun 20, 2021. A meta-analysis was performed to evaluate the affect of SHP2 in clinical stages, disease-free survival (DFS) and overall survival (OS) in tumor patients. <h4>Results</h4> This study showed that the expression of SHP2 had no significant correlation with clinical stages (OR: 0.91; 95% CI, 0.60–1.38; P = 0.65), DFS (HR = 0.88; 95%CI: 0.58–1.34; P = 0.56) and OS (HR = 1.07, 95%CI: 0.79–1.45, P = 0.67), but the prognostic effect varied greatly with tumor sites. High SHP2 expression was positively related to early clinical stage in hepatocellular carcinoma, not associated with clinical stage in the most of solid tumors, containing laryngeal carcinoma, pancreatic carcinoma and gastric carcinoma, etc. Higher expression of SHP2 could predict longer DFS in colorectal carcinoma, while predict shorter DFS in hepatocellular carcinoma. No significant difference was observed in DFS for non-small cell lung carcinoma and thyroid carcinoma. Higher SHP2 expression was distinctly related to shorter OS in pancreatic carcinoma and laryngeal carcinoma. The OS of the other solid tumors was not significantly different. <h4>Conclusions</h4> The prognostic value of SHP2 might not equivalent in different tumors. The prognostic effect of SHP2 is highly influenced by tumor sites.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782321/?tool=EBI |
| spellingShingle | Jiupeng Zhou Hui Guo Yongfeng Zhang Heng Liu Quanli Dou Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysis PLoS ONE |
| title | Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysis |
| title_full | Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysis |
| title_fullStr | Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysis |
| title_full_unstemmed | Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysis |
| title_short | Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysis |
| title_sort | prognostic significance of shp2 ptpn11 expression in solid tumors a meta analysis |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782321/?tool=EBI |
| work_keys_str_mv | AT jiupengzhou prognosticsignificanceofshp2ptpn11expressioninsolidtumorsametaanalysis AT huiguo prognosticsignificanceofshp2ptpn11expressioninsolidtumorsametaanalysis AT yongfengzhang prognosticsignificanceofshp2ptpn11expressioninsolidtumorsametaanalysis AT hengliu prognosticsignificanceofshp2ptpn11expressioninsolidtumorsametaanalysis AT quanlidou prognosticsignificanceofshp2ptpn11expressioninsolidtumorsametaanalysis |